1. Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis
   Shuyan Gu et al, 2020, BMC Medicine CrossRef
2. A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes
   Li-Guo Wang et al, 2017, Biomedicine & Pharmacotherapy CrossRef
3. High‐Throughput Algorithm for Discovering New Drug Indications by Utilizing Large‐Scale Electronic Medical Record Data
   Do‐Hoon Kim et al, 2020, Clinical Pharmacology & Therapeutics CrossRef
4. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open‐label, prospective study (VISION)
   L.‐N. Ji et al, 2016, Diabetes, Obesity and Metabolism CrossRef
5. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis
   Subodh Verma et al, 2017, CMAJ Open CrossRef
6. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates
   Agata Schubert et al, 2017, Current Medical Research and Opinion CrossRef
7. Effect of combined gliclazide/metformin treatment on oxidative stress, lipid profile, and hepatorenal functions in type 2 diabetic patients
   Mansour Alsharidah et al, 2018, Saudi Pharmaceutical Journal CrossRef
8. Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes
   Eleni Bekiari et al, 2016, Endocrine CrossRef